U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644312) titled 'Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG' on May 29.
Brief Summary: The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
Study Start Date: March 01, 2027
Study Type: INTERVENTIONAL
Condition:
High Grade Glioma
Diffuse Intrinsic Pontine Glioma
WHO Grade 3 Glioma
WHO Grade 4 Glioma
Replication Repair Deficient
Intervention:
DRUG: Opdualag
Fixed dose combination of relatlimab and nivolumab (Opdualag)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Nationwide Children's Hospital...